Case Study: Achieving 172% of Enrollment Targets for a Global Phase 3 Trial

Objective

Tekton was selected to deliver research sites and participants for a Global Phase 3 vaccine clinical trial. The trial required a patient population of generally healthy adults aged ≥50, stratified into three age groups.

Challenge

Vaccine season brings a surge of clinical research activity—especially for flu-related studies. At the time of this trial, several similar studies were running simultaneously across the U.S., creating a highly competitive environment for both site activation and participant recruitment. Tekton needed to move fast: activating sites quickly, enrolling efficiently, and standing out among a crowded field—all without compromising quality or participant experience.

Solutions

Key Metrics

%
Average enrollment across 7 sites
Goal: 430 | Enrolled: >720
hours
Average time from activation to first patient visit across 7 sites
days
Average regulatory turnaround time across 7 sites

Accelerated Study Start-Up & Activation

Tekton’s centralized services team leverages a streamlined, proven approach to ensure sites are up and running quickly. With a single point of contact for all site communications, centralized regulatory and IRB coordination, and unified budgeting and contracting processes, sponsors benefit from a fast, predictable, and efficient start-up. Real-time operational dashboards and accurate centralized invoicing keep everything on track and transparent from day one.

Targeted Patient Recruitment

Tekton's approach to recruitment for vaccine studies begins long before flu season. Our dedicated Patient Recruitment Center in Austin, TX maintains a robust database of trial-ready individuals and stays in touch through regular outreach via email, phone calls, and text messages. By pre-identifying potential participants year-round and engaging with diverse communities through local events and initiatives, we ensure rapid enrollment and strong retention when it’s time to launch.

Results

Enrollment began in October 2024 and concluded in November 2024. Through rigorous pre-screening and patient recruitment efforts, Tekton exceeded contracted enrollment goals, achieving 172% of enrollment targets. The first patient visit was scheduled within hours of site activation, and the average across all 7 Tekton sites was less than 12 hours from site activation.

Tekton Sites

  • Austin, TX
  • Beaumont, TX
  • Edmond, OK
  • Fort Collins, CO
  • Longmont, CO
  • San Antonio, TX
  • Yukon, OK
clinical research neurology studies

Partner With Us

Join the leading sponsors and CROs who trust Tekton Research with their most important clinical trials. Contact us today to discuss how our specialized expertise can help bring your next breakthrough treatment to patients in need.